What is the standard BEP (bleomycin, etoposide, cisplatin) chemotherapy regimen, including dosing and schedule, for treating germ‑cell tumors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Standard BEP Chemotherapy Regimen for Germ Cell Tumors

The standard BEP regimen consists of etoposide 100 mg/m² IV on days 1-5, cisplatin 20 mg/m² IV on days 1-5, and bleomycin 30 units IV weekly on days 1,8, and 15, repeated every 21 days. 1, 2, 3, 4

Dosing by Risk Category

The number of cycles depends on IGCCCG (International Germ Cell Cancer Collaborative Group) risk stratification:

Good-Prognosis Disease

  • Three cycles of BEP is the standard treatment 2, 5, 6
  • Alternative: Four cycles of EP (etoposide + cisplatin, omitting bleomycin) if contraindications to bleomycin exist 2, 5
    • Bleomycin contraindications include: reduced lung capacity, emphysema, heavy smoking (including former smokers), or baseline pulmonary dysfunction 2, 6

Intermediate-Prognosis Disease

  • Four cycles of BEP is the standard regimen 2, 5, 6
  • Alternative: Four cycles of VIP (etoposide, ifosfamide, cisplatin) if bleomycin is contraindicated 2, 6

Poor-Prognosis Disease

  • Four cycles of BEP remains standard 2, 5
  • Consider marker-driven dose intensification if unfavorable tumor marker decline after cycle 1 5

Detailed Drug Administration

Etoposide:

  • 100 mg/m² IV daily for 5 consecutive days (days 1-5) 1, 2
  • Total dose per cycle: 500 mg/m²
  • Administer as slow IV infusion over 30-60 minutes 4

Cisplatin:

  • 20 mg/m² IV daily for 5 consecutive days (days 1-5) 1, 2, 3
  • Total dose per cycle: 100 mg/m²
  • Critical hydration protocol: 1-2 liters of fluid infused 8-12 hours before cisplatin, then dilute cisplatin in 2 liters of 5% dextrose in 1/2 or 1/3 normal saline containing 37.5 g mannitol, infused over 6-8 hours 3
  • Maintain adequate hydration and urinary output for 24 hours post-infusion 3

Bleomycin:

  • 30 units IV weekly on days 1,8, and 15 of each 21-day cycle 1, 2
  • Alternative schedule: days 2,9, and 16 1
  • Administer only during the first 3 cycles when giving 4 total cycles 2
  • Obtain baseline pulmonary function tests before initiating bleomycin 7

Cycle Timing and Dose Intensity

Chemotherapy must be recycled every 21 days without delay or dose reduction 5, 6. This strict adherence to schedule is critical for optimal outcomes. Do not proceed with the next cycle until:

  • Serum creatinine <1.5 mg/dL and BUN <25 mg/dL 3
  • Platelets ≥100,000/mm³ and WBC ≥4,000/mm³ 3
  • Audiometric analysis confirms normal auditory acuity 3

Key Clinical Considerations

Bleomycin omission is appropriate when:

  • Active smoking or vaping (including e-cigarettes) 8
  • Age ≥50 years 8
  • Reduced or borderline kidney function 8
  • Baseline pulmonary dysfunction or emphysema 2
  • During ongoing SARS-CoV-2 transmission 8

EP regimen (without bleomycin) requires four cycles to maintain equivalent efficacy to three cycles of BEP 2, 5, 8. The landmark study by Culine et al. 9 demonstrated equivalence of three cycles of BEP with etoposide 500 mg/m² per cycle, establishing this as the standard dose.

Common pitfalls to avoid:

  • Do not use carboplatin instead of cisplatin—carboplatin-based regimens are inferior 10, 6
  • Do not reduce etoposide dose below 500 mg/m² per cycle 9
  • Do not delay cycles beyond 21 days unless medically necessary 5, 11
  • Do not use aluminum-containing needles or IV sets with cisplatin 3

Supportive care requirements:

  • Antiemetics for nausea/vomiting management 4
  • Monitor for thromboembolic events (8.9% incidence) 8
  • Consider primary prophylactic G-CSF for febrile neutropenia risk (16% incidence), particularly in first cycle 8, 11
  • Monitor blood pressure during etoposide infusion for hypotension 4

References

Guideline

testicular cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Guideline

ovarian cancer, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.